ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Specialist

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,478Medicare Part D Prescriptions Filled, Including Refills

Rank: 93 out of 1290

$418K Total Retail Price of All Prescriptions

Rank: 248 out of 1290

416 Patients Receiving at Least One Drug in Part D
88%Patients 65 Years and Older
37% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Florida
Lower avg

Schedule Two
Controlled Substances

8% of this provider’s 416 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

7% of this provider’s 416 patients filled at least one prescription for a schedule three drug, compared to an average of 9%.

Risky Drugs to Seniors

1% of this provider’s 7,541 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 29%.

Prescription Price

$49 was the average price of a prescription from this provider, compared to $94 among peers.

Prescriptions per Patient

20 is the average number of prescriptions (including refills) per patient, compared to an average of 9.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Florida
SIMVASTATIN 461 428 1 1
OMEPRAZOLE 316 290 2 2
METOPROLOL TARTRATE 296 270 3 7
LEVOTHYROXINE SODIUM 285 267 4 4
ATORVASTATIN CALCIUM 235 212 5 23
METFORMIN HCL 227 183 6 10
AMLODIPINE BESYLATE 211 192 7 3
ATENOLOL 202 198 8 18
LOSARTAN POTASSIUM 149 119 9 19
ALENDRONATE SODIUM 136 127 10 39
LISINOPRIL 136 111 10 5
TAMSULOSIN HCL 124 120 12 11
ZOLPIDEM TARTRATE 112 112 13 15
FLUTICASONE PROPIONATE 108 87 14 26
DIOVAN 106 106 15 53
NEXIUM 99 90 16 34
ALPRAZOLAM 88 78 17 47
ENALAPRIL MALEATE 85 84 18 62
GLYBURIDE 83 68 R 19 87
FUROSEMIDE 82 52 20 9
HYDROCHLOROTHIAZIDE 82 82 20 20
CARVEDILOL 82 51 20 12
METOPROLOL SUCCINATE 79 79 23 14
PANTOPRAZOLE SODIUM 77 61 24 48
AMLODIPINE BESYLATE-BENAZEPRIL 77 76 24 166
CITALOPRAM HBR 76 63 26 29
CRESTOR 76 66 26 17
CLONIDINE HCL 76 76 26 66
GABAPENTIN 74 63 29 8
DONEPEZIL HCL 73 68 30 13
CLOPIDOGREL 72 61 31 24
PAROXETINE HCL 72 68 31 84
TEMAZEPAM 68 55 33 71
GEMFIBROZIL 64 64 34 210
DOXAZOSIN MESYLATE 62 62 35 64
PROAIR HFA 62 37 35 73
SYNTHROID 61 61 37 28
HYDRALAZINE HCL 61 49 37 133
HYDROCODONE-ACETAMINOPHEN 58 40 S3 39 6
CIPROFLOXACIN HCL 53 50 40 46
DIOVAN HCT 52 52 41 112
PRAVASTATIN SODIUM 51 27 42 42
ALLOPURINOL 51 38 42 60
VOLTAREN 50 49 44 107
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 2, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.